These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15585001)

  • 1. Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.
    Ford PA; Mastoris J
    Transfusion; 2004 Dec; 44(12 Suppl):15S-25S. PubMed ID: 15585001
    [No Abstract]   [Full Text] [Related]  

  • 2. [Iron deficiency and anemia in oncology].
    Scotté F; Launay-Vacher V; Ray-Coquard I
    Bull Cancer; 2012 May; 99(5):563-70. PubMed ID: 22516641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction. Improving the standard of care in the management of cancer-related anaemia: focus on darbepoetin alfa, a novel erythropoiesis-stimulating protein.
    Glaspy J
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):1-2. PubMed ID: 11308267
    [No Abstract]   [Full Text] [Related]  

  • 4. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia.
    Lappin TR; Maxwell AP; Johnston PG
    Oncologist; 2007 Apr; 12(4):362-5. PubMed ID: 17470677
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythropoietin, the FDA, and oncology.
    Steinbrook R
    N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025
    [No Abstract]   [Full Text] [Related]  

  • 6. Weighing the hazards of erythropoiesis stimulation in patients with cancer.
    Khuri FR
    N Engl J Med; 2007 Jun; 356(24):2445-8. PubMed ID: 17568023
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to "effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia".
    Coiffier B
    Oncologist; 2005 Oct; 10(9):762-3; author reply 764-5. PubMed ID: 16249359
    [No Abstract]   [Full Text] [Related]  

  • 8. Erythropoietin: high profile, high scrutiny.
    Crawford J
    J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
    [No Abstract]   [Full Text] [Related]  

  • 9. Darbepoetin alfa: potential role in managing anemia in cancer patients.
    Pirker R; Smith R
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):377-84. PubMed ID: 12647980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rebates for anti-anemia drugs draw response from FDA, CMS.
    Sipkoff M
    Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
    [No Abstract]   [Full Text] [Related]  

  • 11. Guidelines for the use of recombinant human erythropoietin.
    Barosi G; Cazzola M; De Vincentiis A; Grossi A; Tura S
    Haematologica; 1994; 79(6):526-33. PubMed ID: 7896210
    [No Abstract]   [Full Text] [Related]  

  • 12. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
    Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
    Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia.
    Kara O; Dizdar O; Altundag K
    JAMA; 2008 Dec; 300(24):2855; author reply 2855-7. PubMed ID: 19109113
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer.
    Smith RE; Jaiyesimi IA; Meza LA; Tchekmedyian NS; Chan D; Griffith H; Brosman S; Bukowski R; Murdoch M; Rarick M; Saven A; Colowick AB; Fleishman A; Gayko U; Glaspy J
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):24-30. PubMed ID: 11308271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Erythropoietin resistance].
    Branger B
    Nephrologie; 2002; 23(1):3-5. PubMed ID: 11887576
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of mild anemia.
    Waltzman RJ
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-38-41. PubMed ID: 23570098
    [No Abstract]   [Full Text] [Related]  

  • 17. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy.
    Glaspy J; Jadeja JS; Justice G; Kessler J; Richards D; Schwartzberg L; Rigas J; Kuter D; Harmon D; Prow D; Demetri G; Gordon D; Arseneau J; Saven A; Hynes H; Boccia R; O'Byrne J; Colowick AB
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):17-23. PubMed ID: 11308270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of recombinant human erythropoietin outside the setting of uremia.
    Cazzola M; Mercuriali F; Brugnara C
    Blood; 1997 Jun; 89(12):4248-67. PubMed ID: 9192747
    [No Abstract]   [Full Text] [Related]  

  • 19. Recombinant human erythropoietin corrects anemia of blood loss: a study in the dog.
    Koumegawa J; Kawahara J; Kubo K; Amano K; Wakimoto N; Takahashi K; Juji T; Takaku F
    Int J Cell Cloning; 1990 Mar; 8(2):97-106. PubMed ID: 2313141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
    Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
    Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.